The Expanded Access Program will provide access and assess the safety of AMX0035 for the treatment of people living with ALS.
AMX0035 is a combination therapy designed to reduce neuronal death through blockade of key cellular death pathways originating in the endoplasmic reticulum (ER) and mitochondria. This Expanded Access Program is designed to provide expanded access to AMX0035 for the treatment of people living with ALS and assess safety in diverse populations/stages of ALS over 48 weeks.
Inclusion Criteria:
- Male or female, at least 18 years of age (inclusive);
- Diagnosis of ALS made by a physician experienced with the management of ALS;
- >36 months from symptom onset defined as first weakness
- Capable of providing informed consent;
- Capable of and willing to follow program procedures.
- Participants who have established care with a physician experienced in treating
patients with ALS involved in the program and will maintain this clinical care
throughout the duration of their time in the program.
- Women of childbearing potential (e.g., not post-menopausal for at least one year or
surgically sterile) must agree to use adequate birth control for the duration of the
program and 3 months after last dose of AMX0035;
- Women must not be planning to become pregnant for the duration of the program and
3 months after last dose of study drug
- Men must agree to practice contraception for the duration of the program and for at
least 3 months after last dose of program drug;
- Men must not plan to father a child or provide sperm
Exclusion Criteria
- Currently enrolled in a therapeutic study involving the use of an investigational
therapy;
- Dependence on invasive mechanical ventilation, defined as being unable to lay supine
without it, unable to sleep without it, or continuous daytime use; presence of
tracheostomy at Screening;
- No current need for tracheostomy or PAV (defined as more than 22 hours daily of
mechanical ventilation for more than one week (7 days) or based on the site
investigator's judgment; no need anticipated for the next 12 weeks
- In the judgment of the Investigator, the participant's expected survival is less than
6 months
- History of known allergy to the following: PB, bile salts, excipient/constituents of
the formulation;
- Abnormal liver function defined as AST and/or ALT >3 times the upper limit of the
normal (obtained within 12 weeks from first dose);
- Renal insufficiency as defined by eGFR <60 mL/min/1.73m2 (obtained within 12 weeks
from first dose);
- Pregnant women or women currently breastfeeding;
- Current severe biliary disease which may result in the investigator medical judgement
in biliary obstruction including for example active cholecystitis, primary biliary
cirrhosis, sclerosing cholangitis, gallbladder cancer, gallbladder polyps, gangrene of
the gallbladder, abscess of the gallbladder;
- History of Class III/IV heart failure (per New York Heart Association - NYHA);
- Participant under severe salt restriction where the added salt intake due to treatment
would put the participant at risk, in the Site Investigator clinical judgment;
- Presence of unstable psychiatric disease, cognitive impairment, dementia or substance
abuse that would impair ability of the participant to provide informed c consent,
according to Site Investigator judgment;
- Clinically significant unstable medical condition (other than ALS) that would pose a
risk to the participant if they were to participate in the program, according to Site
Investigator judgment;
- Treatment, current or within 90 days from screening with any cell therapies or gene
therapies;
- Implantation of Diaphragm Pacing System (DPS);
- Anything that, in the opinion of the Site Investigator, would place the participant at
increased risk or preclude the participant's full compliance with or completion of the
program;
- Current or planned exposure to any prohibited medications listed in Section 6.8.1 of
the protocol